A Retrospective Comparative Study on Median Time to Sputum Culture Conversion in Multi-Drug Resistant Pulmonary Tuberculosis Patients in Pastoral and Non-Pastoral Settings in Southeast Oromia, Ethiopia

Figures & data

Figure 1 Comparison of the median time (days) to sputum culture between patients from the pastoral and non-pastoral setting, southeastern Oromia, Ethiopia, 2021.

Table 1 Association of the Socio-Demographic Characteristics with the TTSCC Among MDR/RR-TB Patients in Southeastern Oromia, Ethiopia, 2021

Variables	Number	Percent	CHR (95% CI)	AHR (95% CI)
Age category
Less than 15 years	15	3.36	1.00	1.00
15–30 years	272	60.85	1.14 (0.62–2.09)	0.82 (0.42–1.56)
31–45 years	100	22.37	1.09 (0.58–2.04)	0.98 (0.50–1.93)
46 or older	60	13.42	1.37 (0.71–2.65)	1.40 (0.68–2.90)
Residence
Urban	231	51.68	1.00	1.00
Rural	216	48.32	0.69 (0.57–0.85)	1.12 (0.88–1.44)
Marital status
Single	147	32.89	1.00	1.00
Married	264	59.06	0.87 (0.70–1.08)	0.86 (0.68–1.08)
Divorced	32	7.16	2.12 (1.42–3.17)	1.35 (0.87–2.08)
Widowed	4	0.89	2.45 (0.90–6.66)	1.69 (0.61–4.66)
Educational status
No formal education	171	38.26	1.00	1.00
Primary	138	30.87	1.24 (0.98–1.58)	1.18 (0.89–1.57)
Secondary	103	23.04	1.68 (1.29–2.18)	1.48 (1.08–2.03)*
College and above	35	7.83	1.62 (1.11–2.38)	1.47 (0.92–2.33)
Occupation
Farmer/House wife	187	41.83	1.00	1.00
Employed (gov’t/self)	134	29.98	2.24 (1.74–2.87)	1.36 (0.96–1.93)
Merchant/daily laborer/Student	126	28.19	2.39 (1.86–3.08)	1.63 (1.20–2.22)**
Livelihood setting
Pastoral	177	39.60	0.29 (0.23–0.37)	0.31 (0.24–0.41)***
Non-pastoral	270	60.40	1.00	1.00

Notes: *p-value <0.05; **P-value <0.01; ***p-value <0.001.

Table 2 Association of Clinical Characteristics with the TTSCC Among MDR/RR-TB Patients in Southeastern Oromia, Ethiopia, 2021

Variables	Number	Percent	COR (95% CI)	COR (95% CI)
Body mass index (BMI)
Less than 18.5 Kg/SqM	159	37.15	1.00	1.00
18.5 or higher Kg/SqM	269	62.85	1.12 (0.91–1.39)	1.35 (1.07–1.71)*
Resistance type
RR	382	85.46	1.64 (1.25–2.15)	1.26 (0.89–1.79)
MDR	65	14.54	1.00	1.00
Treatment registration Group
New	149	33.33	1.00	1.00
Relapse	119	26.62	1.07 (0.83–1.39)	1.01 (0.76–1.33)
After failure	179	40.04	1.88 (1.48–2.38)	1.40 (1.06–1.84)*
Comorbid disease condition
No	381	85.23	1.00	1.00
Yes	66	14.77	0.75 (0.57–1.00)	0.91 (0.67–1.23)
Previously treated with second-line anti TB drug
No	410	91.72	1.00	1.00
Yes	37	8.28	2.38 (1.67–3.38)	1.43 (0.89–2.28)
Intensive phase drug regimen
Cm,Lfx,Cs,Pto(Eto),Z	188	42.06	1.00	1.00
Cm,Lfx,Eto,CS,Z	173	38.70	0.38 (0.30–0.48)	0.33 (0.25–0.45)
H,E,Z,AM,Mfx,Pto	13	2.91	1.33 (0.76–2.34)	3.12 (1.36–7.14)**
H,E,Z,Km,Mfx,Pto,Cfx	37	8.28	0.34 (0.23–0.49)	0.55 (0.28–1.08)
Z,Km,Mfx,PAS,Bdq,Cfz	36	8.05	0.39 (0.23–0.67)	0.23 (0.12–0.45)***
Continuation phase drug regimen
E,Z,Mfx,Cfx	50	11.19	1.00	1.00
Lfx,CS,Bdq,Cfx,Lzd	22	4.92	2.94 (1.70–5.08)	2.48 (1.22–5.07)*
Lfx,CS,Eto,Z,B6	368	82.33	1.29 (0.94–1.76)	1.88 (0.97–3.64)
Z,Mfx,PAS,Cfz,LZD	7	1.57	2.99 (1.34–6.71)	6.45 (2.45–16.96)***

Notes: *p-value <0.05; **P-value <0.01; ***p-value <0.0.